NeonMind Appoints Canadian Medical Leader in Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC to Its Specialty Clinics Advisory Board
NeonMind Appoints Canadian Medical Leader in Anesthesiology, Dr. Daniel Bainbridge, MD,FRCPC to Its Specialty Clinics Advisory Board
Dr. Bainbridge’s Expertise and Network Provides Safety Best-Practices for Administration ofIntravenous Ketamine (IV-Ketamine) at NeonMind Clinics
Vancouver, B.C. – January 13, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA:6UF) (“NeonMind'' or the “Company”), an integrated drug development and wellness company,announced today the appointment of Dr. Daniel Bainbridge, MD, FRCPC, past President of the CanadianAnesthesiologists Society, Professor from the Department of Anesthesia and Perioperative Medicine atthe University of Western Ontario, and Anesthesia Consultant at London Health Sciences Centre, to itsSpecialty Clinics Advisory Board.
NeonMind’s medical services division is establishing specialty clinics to enhance access to interventionalpsychiatry treatments including intravenous ketamine treatment (“IV-ketamine”) which has shownpromise as a rapid treatment for mood and anxiety disorders and has been included as a recommendedtreatment into Canadian guidelines by the Canadian Network for Mood and Anxiety Treatments
1
. Dr.Bainbridge will utilize his substantial experience to ensure NeonMind’s protocols, procedures, training,and practices of administering intravenous ketamine are best-in-class and practical from a safetyperspective. With over 20 years as a practicing anesthesiologist and his leadership role with the
Canadian Anesthesiologists Society, Dr. Bainbridge has vast experience with ketamine and a largenetwork of contacts for NeonMind to train and employ to assure patient safety.
“We are excited to welcome the Canadian leader in anesthesiology, Dr. Bainbridge, to our SpecialtyClinics Advisory Board. At NeonMind, we are focused on enhancing access to interventional psychiatry tohelp address the mental health crisis, including IV-ketamine for mood and anxiety disorders. Safety is ofutmost importance for NeonMind’s specialty clinics and, with Dr. Bainbridge’s involvement in buildingour programs, we can assure patients and healthcare providers they are receiving best-in-class care fortheir IV-ketamine administration. He will prove invaluable to enhancing access and wider adoption ofNeonMind’s IV-ketamine treatment programs,” said Robert Tessarolo, President & CEO of NeonMind.
Dr. Bainbridge commented, “The evidence supports that IV-ketamine is safe and well tolerated at thetherapeutic doses used to treat patients suffering from mood and anxiety disorders. The ketamine dosesused are magnitudes lower than for procedural sedation, let alone general anesthesia. Ketamineadministration requires specific procedures and expertise and can be safely provided in specialty clinicswith the appropriately trained health care provider. My colleagues at NeonMind understand this withthe aim of enhancing access to this transformational treatment for mood and anxiety disorders utilizingsafe and effective care programs. I am excited to work with NeonMind in developing IV-ketamineadministration practices and establishing a clinic network to enhance access to these treatmentprograms for patients in need.”
1. Swainson, J., McGirr, A., Blier, P., Brietzke, E., Richard-Devantoy, S., Ravindron, N., Blier, J., McIntyre, R., Milev, R., Parikh, S.,Schaffer, A., Taylor, V., Tourjman, V., van Ameringen, M., Yatham, L., Ravindran, A. and Lam, R., 2021. The Canadian Network forMood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with MajorDepressive Disorder. The Canadian Journal of Psychiatry, 66(12), pp.1102-1102.
About NeonMind Biosciences Inc.
NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development ofpsychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) amedical services division focused on launching specialty mental health clinics that integrate psychedelictherapeutics into traditional psychotherapy settings.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programstargeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at theserotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’ssecond drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor,which controls appetite.
NeonMind and its strategic partners are building NeonMind-branded specialty mental health clinics inCanada that incorporate evidence-backed innovative treatments to address a variety of mental healthneeds. For more information on NeonMind, go to www.NeonMindBiosciences.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences [email protected]: 416-750-3101
Investor Relations:
KCSA Strategic CommunicationsScott Eckstein/Tim [email protected]: 212-896-1210
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this newsrelease.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. Thesestatements relate to future events or NeonMind’s future performance. The use of any of the words"could", "expect", "believe", "will", "projected", "estimated" and similar expressions and statementsrelating to matters that are not historical facts are intended to identify forward-looking information andare based on NeonMind’s current belief or assumptions as to the outcome and timing of such futureevents. Actual future results may differ materially. In particular, NeonMind’s drug development plans, itsability to retain key personnel, and its expectation as to the development of its intellectual property andother steps in its preclinical and clinical drug development constitute forward-looking information. Actualresults and developments may differ materially from those contemplated by forward-lookinginformation. Readers are cautioned not to place undue reliance on forward-looking information. Thestatements made in this press release are made as of the date hereof. NeonMind disclaims any intentionor obligation to publicly update or revise any forward-looking information, whether as a result of newinformation, future events or otherwise, except as may be expressly required by applicable securitieslaws.